750 Participants Needed

Enhanced Symptom Management for Cancer

AO
RW
Overseen ByRyan W Huey, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This clinical trial studies if enhanced outpatient symptom management with telemedicine and remote monitoring can help reduce acute care visit due to chemotherapy-related adverse events. Receiving telemedicine and remote monitoring may help patients have better outcomes (such as fewer avoidable emergency room visits and hospitalizations, better quality of life, fewer symptoms, and fewer treatment delays) than patients who receive usual care.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems likely that you can continue your current treatments, especially since the trial involves outpatient chemotherapy.

What data supports the effectiveness of the treatment Enhanced Outpatient Symptom Management with Telemedicine and Remote Monitoring for cancer patients?

Research shows that remote monitoring tools and telemedicine can help manage symptoms in cancer patients, potentially reducing unplanned hospital visits and improving quality of life. Studies have found that telemedicine, including videoconferencing, is effective in outpatient care for cancer patients, and remote symptom management can optimize self-care and healthcare use during chemotherapy.12345

Is the Enhanced Symptom Management for Cancer treatment safe for humans?

The treatment, which involves remote monitoring and telemedicine, has been used in cancer care to manage symptoms and improve patient outcomes. It has shown benefits in economic and survival outcomes, suggesting it is generally safe for use in humans.36789

How is the Enhanced Outpatient Symptom Management with Telemedicine and Remote Monitoring treatment different from other cancer treatments?

This treatment is unique because it uses telemedicine and remote monitoring to manage cancer symptoms, allowing patients to receive care at home and reducing the need for emergency visits. It focuses on real-time symptom tracking and personalized support, which can improve quality of life and treatment compliance.34101112

Research Team

RW

Ryan W Huey, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults with metastatic cancers of the thoracic and gastrointestinal regions, starting outpatient chemotherapy at MD Anderson Cancer Center. Caregivers can participate with patient consent. Excluded are those on investigational drugs, in phase 1 trials, requiring inpatient infusion, living in institutions like prisons, or with dementia or disabilities preventing symptom reporting.

Inclusion Criteria

I am an adult with cancer in the chest or digestive system starting chemotherapy at MDACC.
I am an adult caregiver for a patient.
Patients may participate if they do not have a caregiver, or if their caregiver declines participation; however, caregivers may participate only if the patient consents

Exclusion Criteria

I cannot report my symptoms due to dementia, physical disability, or neurological issues.
You are currently taking part in a study for a new medication or treatment.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive standard oncology care via telemedicine, with some undergoing additional remote and biometric monitoring

3 months
Regular telemedicine visits

Follow-up

Participants are monitored for safety and effectiveness after treatment, focusing on acute care visits and quality of life

3 months

Treatment Details

Interventions

  • Enhanced Outpatient Symptom Management with Telemedicine and Remote Monitoring
Trial OverviewThe study tests if enhanced outpatient symptom management using telemedicine and remote monitoring reduces emergency visits due to chemotherapy side effects compared to usual care. It aims for better patient outcomes including quality of life and fewer treatment delays.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Arm III (standard of care, remote monitoring, biometrics)Experimental Treatment3 Interventions
Patient receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring and biometric monitoring.
Group II: Arm II (standard of care, remote monitoring)Experimental Treatment3 Interventions
Patients receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring.
Group III: Arm I (standard of care)Active Control2 Interventions
Patients receive standard of care consisting of oncology care provided via telemedicine.

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

Findings from Research

In a study involving 864 oncology patients, only 39% of those with severe symptoms were receptive to a remote nurse-led symptom care management phone call, indicating a significant gap in patient engagement with supportive care interventions.
The study found that patients were more likely to accept the call if they were in an opt-out system, receiving care at a tertiary center, or experiencing severe pain, suggesting that these factors could influence the effectiveness of symptom-focused interventions.
Receptivity to a Nurse-Led Symptom Management Intervention Among Highly Symptomatic Patients With Cancer.Wintheiser, GA., Ruddy, KJ., Herrin, J., et al.[2022]
A pilot study involving 77 women undergoing chemotherapy for early stage breast cancer showed that a telephone symptom management intervention was feasible and well-received, with 83.8% of scheduled calls delivered.
Patients receiving the intervention had significantly fewer emergency department visits compared to controls, indicating that proactive symptom management may help reduce acute care utilization during chemotherapy.
Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer.Krzyzanowska, MK., MacKay, C., Han, H., et al.[2022]
A prototype web-based tool was developed to help manage chemotherapy-related symptoms, based on user feedback from 14 patients, 1 caregiver, and 12 healthcare providers, highlighting the need for better communication and decision aids in cancer care.
Usability testing with 22 participants showed positive feedback for the tool's features like toxicity tracking and self-management advice, but also revealed challenges in integrating the tool into existing healthcare workflows and ensuring patient privacy.
User-Centered Design of a Web-Based Tool to Support Management of Chemotherapy-Related Toxicities in Cancer Patients.Prince, RM., Soung Yee, A., Parente, L., et al.[2020]

References

Receptivity to a Nurse-Led Symptom Management Intervention Among Highly Symptomatic Patients With Cancer. [2022]
Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer. [2022]
User-Centered Design of a Web-Based Tool to Support Management of Chemotherapy-Related Toxicities in Cancer Patients. [2020]
The assessment of telemedicine to support outpatient palliative care in advanced cancer. [2015]
Efficacy of Telemedicine Using Videoconferencing Systems in Outpatient Care for Patients With Cancer: A Systematic Review and Meta-Analysis. [2023]
Adaptation of Remote Symptom Monitoring Using Electronic Patient-Reported Outcomes for Implementation in Real-World Settings. [2023]
Remote Oncology Care: Review of Current Technology and Future Directions. [2020]
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. [2021]
The Patient Remote Intervention and Symptom Management System (PRISMS) - a Telehealth- mediated intervention enabling real-time monitoring of chemotherapy side-effects in patients with haematological malignancies: study protocol for a randomised controlled trial. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Analysis of Unscheduled Telephone Calls Received by a Specialized Cancer Pain Nurse. [2021]
11.United Statespubmed.ncbi.nlm.nih.gov
Electronic Patient Symptom Management Program to Support Patients Receiving Cancer Treatment at Home During the COVID-19 Pandemic. [2022]
The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer. [2019]